MeSH term
Frequency | Condition_Probility | Humans | 200 | 0.0 |
Animals | 85 | 0.0 |
Cell Line | 26 | 0.0 |
*Genome, Viral | 2 | 2.0 |
Plasmids | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 46 | 0.0 |
DNA, Complementary | 2 | 0.0 |
*Genes, Viral | 8 | 4.0 |
RNA, Viral/metabolism | 2 | 2.0 |
Recombination, Genetic | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 106 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
*Virus Replication | 4 | 1.0 |
Adult | 51 | 0.0 |
Female | 71 | 0.0 |
Male | 65 | 0.0 |
Middle Aged | 39 | 0.0 |
Neuropsychological Tests | 3 | 1.0 |
*Schizophrenic Psychology | 2 | 3.0 |
Aged | 27 | 0.0 |
Biopsy | 3 | 0.0 |
Disease Progression | 2 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
Prospective Studies | 2 | 0.0 |
Cells, Cultured | 11 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Comparative Study | 45 | 0.0 |
Molecular Sequence Data | 34 | 0.0 |
Nucleoproteins/*genetics | 6 | 66.0 |
Phylogeny | 7 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Viral Core Proteins/*genetics | 4 | 44.0 |
Viral Proteins/*genetics | 3 | 3.0 |
Antibodies, Viral/blood | 2 | 1.0 |
Cercopithecus aethiops | 6 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Mumps virus/*immunology | 2 | 50.0 |
Recombinant Proteins/genetics/immunology/metabolism | 2 | 8.0 |
Vero Cells | 6 | 2.0 |
Adolescent | 13 | 0.0 |
Aged, 80 and over | 8 | 0.0 |
Biological Markers | 2 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Risk Factors | 3 | 0.0 |
Mice | 27 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
RNA, Viral/*genetics | 2 | 4.0 |
*Sequence Homology, Nucleic Acid | 2 | 2.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Base Sequence | 20 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
English Abstract | 24 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Epitopes/immunology | 3 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
*RNA-Binding Proteins | 11 | 3.0 |
*Viral Proteins | 4 | 2.0 |
Evolution, Molecular | 2 | 0.0 |
Genotype | 6 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Hemagglutination Inhibition Tests | 4 | 8.0 |
Lung/virology | 2 | 22.0 |
Precipitin Tests | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 12 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Swine | 5 | 0.0 |
Vaccination | 3 | 1.0 |
Coronary Artery Bypass | 2 | 3.0 |
Hydrolysis | 2 | 0.0 |
Amino Acid Sequence | 25 | 0.0 |
Cell Division | 5 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Epitopes | 6 | 0.0 |
Interferon Type II/biosynthesis | 3 | 0.0 |
Mice, Inbred BALB C | 9 | 0.0 |
Mutation | 7 | 0.0 |
Protein Binding | 5 | 0.0 |
Rats | 10 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Time Factors | 8 | 0.0 |
Dogs | 11 | 0.0 |
Nucleoproteins/*metabolism | 5 | 45.0 |
Species Specificity | 13 | 0.0 |
Gene Expression Regulation, Viral | 3 | 1.0 |
Hela Cells | 7 | 0.0 |
Influenza A Virus, Human/genetics/*metabolism | 2 | 66.0 |
RNA, Viral/*biosynthesis/metabolism | 2 | 100.0 |
Alleles | 4 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Brain Chemistry | 2 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
Eosinophil Granule Proteins | 2 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
*Ribonucleases | 2 | 0.0 |
Fibroblasts/enzymology | 2 | 1.0 |
*Lymphocyte Activation | 2 | 0.0 |
*Nucleoproteins | 6 | 66.0 |
T-Lymphocytes, Cytotoxic/*immunology | 5 | 0.0 |
Viral Core Proteins/immunology | 2 | 8.0 |
RNA, Viral/analysis | 2 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cattle | 5 | 0.0 |
Chickens | 2 | 0.0 |
Chromosome Mapping | 8 | 0.0 |
DNA/genetics | 3 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Influenza A Virus, Human/*genetics | 4 | 80.0 |
Acute Disease | 4 | 0.0 |
Child | 8 | 0.0 |
Child, Preschool | 8 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Infant | 4 | 0.0 |
*Magnetic Resonance Imaging | 2 | 1.0 |
Prognosis | 6 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Clone Cells | 2 | 0.0 |
Epitope Mapping | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Seroepidemiologic Studies | 2 | 1.0 |
Survival Rate | 3 | 0.0 |
Influenza A Virus, Human/*metabolism | 2 | 50.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Binding Sites | 4 | 0.0 |
Nucleoproteins/genetics/*metabolism | 2 | 50.0 |
RNA, Viral/*metabolism | 3 | 6.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
Viral Core Proteins/genetics/*metabolism | 2 | 16.0 |
Hamsters | 5 | 0.0 |
RNA, Viral/*biosynthesis | 3 | 14.0 |
Temperature | 8 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Viral Core Proteins/*metabolism | 4 | 36.0 |
Viral Proteins/analysis | 2 | 8.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Virus Replication/genetics | 2 | 4.0 |
Cardiac Pacing, Artificial | 2 | 4.0 |
In Vitro | 8 | 0.0 |
Chronic Disease | 3 | 0.0 |
DNA Primers | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Genome, Viral | 4 | 3.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Administration, Intranasal | 2 | 2.0 |
Double-Blind Method | 4 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
COS Cells | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Antigens, Viral/*immunology | 6 | 6.0 |
Nucleoproteins/genetics/immunology | 2 | 66.0 |
Macromolecular Substances | 3 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Chick Embryo | 7 | 1.0 |
RNA, Viral/genetics | 5 | 5.0 |
Virus Replication | 4 | 0.0 |
*Point Mutation | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Blood Pressure | 3 | 0.0 |
Rats, Inbred SHR | 2 | 2.0 |
Sex Factors | 2 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Transfection | 6 | 0.0 |
*Evolution | 3 | 1.0 |
Genetic Markers | 6 | 0.0 |
Genes, Viral | 4 | 1.0 |
Infant, Newborn | 3 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Pregnancy | 8 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
*Gene Expression | 3 | 0.0 |
Protein Conformation | 5 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
*Antibody Formation | 2 | 2.0 |
Nucleoproteins/*physiology | 2 | 50.0 |
*Protein Biosynthesis | 2 | 0.0 |
Cadmium Chloride/administration & dosage/*toxicity | 2 | 100.0 |
Cadmium Poisoning/*etiology | 2 | 100.0 |
*Diet | 4 | 1.0 |
Eating/drug effects | 2 | 5.0 |
*Ovariectomy | 3 | 6.0 |
Parity | 4 | 3.0 |
Body Weight/drug effects | 2 | 1.0 |
Bone Density/*drug effects | 2 | 6.0 |
Calcium/analysis | 2 | 6.0 |
Femur/chemistry/drug effects | 2 | 100.0 |
Mice, Inbred CBA | 3 | 0.0 |
Substrate Specificity/immunology | 2 | 13.0 |
*HIV-1 | 2 | 0.0 |
Influenza A virus/immunology | 3 | 23.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Influenza Vaccines/*immunology | 2 | 10.0 |
Nucleoproteins/*immunology | 4 | 50.0 |
Viral Core Proteins/*immunology | 2 | 28.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Kinetics | 7 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
RNA, Viral/*analysis | 2 | 3.0 |
Animals, Newborn | 2 | 0.0 |
Influenza A Virus, Human/*immunology | 3 | 10.0 |
Viral Proteins/genetics | 2 | 3.0 |
Influenza A Virus, Avian/*genetics | 3 | 100.0 |
Saimiri | 2 | 6.0 |
*Circadian Rhythm | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Virulence/genetics | 2 | 2.0 |
Brain/enzymology | 2 | 1.0 |
Neopterin | 5 | 5.0 |
Karyotyping | 5 | 0.0 |
Biopterin/*analogs & derivatives/blood | 3 | 13.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Orthomyxoviridae/*genetics | 2 | 28.0 |
Drug Stability | 2 | 0.0 |
Sex Distribution | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Nucleoproteins/immunology | 4 | 33.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Influenza A virus/*immunology | 4 | 25.0 |
Viral Matrix Proteins/*genetics | 2 | 12.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Molecular Weight | 4 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Radioimmunoprecipitation Assay | 2 | 8.0 |
Evolution | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Viral Proteins/*immunology | 2 | 5.0 |
*Linkage (Genetics) | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Cross Reactions | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Heart Rate/drug effects | 2 | 0.0 |
Pressoreceptors/*physiology | 2 | 16.0 |
Influenza A virus/*genetics | 2 | 50.0 |
Antibodies, Viral/*analysis | 2 | 3.0 |
Organ Specificity | 2 | 0.0 |
*Chromosome Mapping | 5 | 0.0 |
Hemodynamic Processes/*drug effects | 3 | 2.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Horses | 3 | 2.0 |
Pentosyltransferases/*deficiency | 4 | 11.0 |
Purine-Nucleoside Phosphorylase/*deficiency | 2 | 50.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Drug Evaluation | 2 | 0.0 |
Myocardium/metabolism | 3 | 1.0 |
Propoxyphene/*analogs & derivatives/*metabolism | 2 | 100.0 |
Cell Count | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Motor Activity/genetics/physiology | 2 | 40.0 |
Neurophysins/metabolism | 2 | 50.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Peptide PHI/metabolism | 2 | 50.0 |
Statistics, Nonparametric | 2 | 0.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Clinical Trials | 3 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Radioimmunoassay | 2 | 0.0 |
Ferricyanides/*therapeutic use | 3 | 100.0 |
Vascular Resistance/*drug effects | 2 | 15.0 |
Enzymes/*genetics | 3 | 7.0 |
*Genes, Structural | 5 | 0.0 |
Hybrid Cells | 4 | 0.0 |
Rabbits/*genetics | 2 | 12.0 |
Mathematics | 2 | 1.0 |
*Genes | 2 | 0.0 |
Questionnaires | 3 | 0.0 |
Influenza A virus/genetics | 2 | 100.0 |
Influenza A virus/*analysis | 2 | 100.0 |
Nucleoproteins/*analysis/classification | 2 | 100.0 |
Oligopeptides/analysis | 2 | 28.0 |
B-Lymphocytes/enzymology | 2 | 5.0 |
Pentosyltransferases/*metabolism | 3 | 23.0 |
Purine-Nucleoside Phosphorylase/*metabolism | 2 | 50.0 |
T-Lymphocytes/enzymology | 2 | 5.0 |
Erythrocytes/enzymology | 2 | 0.0 |
*Chromosomes, Human, 13-15 | 7 | 24.0 |
Creatine Kinase/*genetics | 2 | 10.0 |
Hybrid Cells/enzymology | 2 | 3.0 |
Linkage (Genetics) | 2 | 0.0 |
Translocation, Genetic | 4 | 0.0 |
Nucleoside Deaminases/*metabolism | 2 | 40.0 |
Electrophoresis, Starch Gel | 2 | 1.0 |
Immunologic Deficiency Syndromes/*enzymology | 2 | 100.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Pentosyltransferases/*biosynthesis | 2 | 100.0 |
Purine-Nucleoside Phosphorylase/*biosynthesis | 2 | 66.0 |
Oxygen Consumption/drug effects | 2 | 5.0 |
